|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Investigations |
Brain Tumor Center (T.T.B.) and Division of Hematology and Medical Oncology (J.G.S.), Massachusetts General Hospital, Boston, MA 02114; Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 (M.R.G.); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 (K.A.C., S.A.G.); Department of Neurology, University of Alabama, Birmingham, AL 35294 (L.B.N.); Department of Hematology and Oncology, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157 (G.J.L.); Henry Ford Hospital, Detroit, MI 48202 (T.M.); Division of Neuro-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612 (S.P.); USA
2 Address correspondence to Stuart A. Grossman, The Sidney Kimmel Comprehensive Cancer Center, G87 Bunting-Blaustein Research Building, 1650 Orleans St., Baltimore, MD 21231-1000, USA (grossman{at}jhmi.edu).
Abstract
The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.
References
Armand, J.P., Extra, Y.M., Catimel, G., Abigerges, D., Marty, M.,
and Clavel, M. (1996) Rationale for the dosage and schedule of
CPT-11 (irinotecan) selected for phase II studies, as determined by European
phase I studies. Ann. Oncol.
7, 837-842.
Bleiberg, H., and Cvitkovic, E. (1996) Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European per spective. Eur. J. Cancer. 32A,S18 -S23.
CBTRUS. Central Brain Tumor Registry of the United States (2002). Statisti cal Report: Primary Brain Tumors in the United States, 1995-1999. Chicago: Central Brain Tumor Registry of the United States (available at http://www.cbtrus.org/2002/2002report.pdf).
Cloughesy, T., Filka, E., Friedman, H., Kabbinavar, F., Kuhn, J., Selch, M., and Miller, L. (2000) A phase I (intrapatient dose escalation) open-label study of irinotecan (CPT-11) in patients with recurrent or progressive malig nant glioma. Proc. Am. Soc. Clin. Oncol. 19,161a (abstract).
Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S. (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41,485 -490.[CrossRef][Web of Science][Medline]
Colvin, O.M., Cokgor, I., Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J.N., Quinn, J.A., Stewart, B., McLendon, R.E., Provenzale, J.M., Sampson, J.H., Haglund, M.M. [and Beason, R., Miller, L., Zaknoen, S., Fraass, U., Dugan, M., Bigner, D., Stafford-Fox, V., Cohen, L., Friedman, A., and Friedman, H.] (2000) Phase I trials of Gliadel plus CPT-11 or Temodar. Proc. Am. Soc. Clin. Oncol. 19, 172a. (Abstract)
Conrad, C.A., Milosavljevic, V.P., and Yung, W.K. (1995) Advances in chemotherapy for brain tumors. Neurol. Clin. 13,795 -812.[Web of Science][Medline]
Fetell, M.R., Grossman, S.A., Fisher, J.D., Erlanger, B., Rowinsky, E., Stockel, J., and Piantadosi, S. (1997) Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology and drug interactions. New Ap proaches to Brain Tumor Therapy Central Nervous System Consortium. J. Clin. Oncol. 15,3121 -3128.[Abstract]
Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71,2585 -2597.[CrossRef][Web of Science][Medline]
Friedman, A.H., Quinn, J.A., Tourt-Uhlig, S., Rich, J.N., Stewart, E.S., Affronti, M.L., Provenzale, J., McLendon, R., Gururangan, S., Buchanan, W., Colvin, O.M., Bigner, D.D., Beason, R., Sampson, J., Haglund, M., Miller, L., and Friedman, H.S. (2001) Phase I trial of CPT-11 plus BCNU in malignant glioma. Proc. Am. Soc. Clin. Oncol. 20, 64a (abstract).
Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby,
T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughesy,
T. Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner,
D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring,
G.L., and Miller, L.L. (1999) Irinotecan therapy in adults with
recurrent or progressive malignant glioma. J. Clin.
Oncol. 17,1516
-1525.
Gilbert, M.R., Supko, J.G., Batchelor, T., Lesser, G., Fisher,
J.D., Piantadosi, S., and Grossman, S. (2003) Phase I clinical
trial and pharmacokinetic study of irinotecan in adults with recurrent
malignant glioma. Clin. Cancer Res.
9,2940
-2949.
Grossman, S.A., Hochberg, F., Fisher, J., Chen, T.-L., Kim, L., Gregory, R., Grochow, L.B., and Piantadosi, S. (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother. Pharmacol. 42,118 -126.[CrossRef][Web of Science][Medline]
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T.M., Vokes, E.E., and Ratain, M.J. (1997a) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol. 15,1502 -1510.[Abstract]
Gupta, E., Wang, X., Ramirez, J., and Rattain, M.J. (1997b) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by val proic acid and phenobarbital. Cancer Chemother. Pharmacol. 39,440 -444.[CrossRef][Web of Science][Medline]
Hare, C.B., Elion, G.B., Houghton, P.J., Houghton, J.A., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S. (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 39,187 -191.[CrossRef][Web of Science][Medline]
Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incom plete observations. J. Am. Stat. Assoc. 53,457 -481.[CrossRef][Web of Science]
Masuda, N., Kudoh, S., and Fukuoka, M. (1996) Irinotecan (CPT-11): Pharmacology and clinical applications. Crit. Rev. Oncol. Hematol. 24,3 -26.[Web of Science][Medline]
Matsumoto, Y., Fujiwara, T., Honjo, Y., Sasaoka, N., Tsuchida, T., and Nagao, S. (1993) Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin 11. J. Surg. Oncol. 53,97 -103.[Web of Science][Medline]
NCI. National Cancer Institute (1999) Common Toxicity Criteria version 2.0. Available at https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ctc000w$.startup.
O'Reilly, S., and Rowinsky, E.K. (1996) The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit. Rev. Oncol. Hematol. 24, 47-70.[Web of Science][Medline]
Patel, V.J., Elion, G.B., Houghton, P.J., Keir, S., Pegg, A.E.,
Johnson, S.P., Dolan, M.E., Bigner, D.D., and Friedman, H.S.
(2000) Schedule-depend ent activity of temozolomide plus CPT-11
against a human central nervous system tumor-derived xenograft.
Clin. Cancer Res. 6,4154
-4157.
Prados, M., Kuhn, J., Yung, W.A., Robbins, H.I., Fink, K., Greenberg, H., Junck, L., Cloughesy, T., Chang, S., Fine, H., Schiff, D., and Nicholas, M.K. (2000) A phase-1 study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Con sortium (NABTC) study. Proc. Am. Soc. Clin. Oncol. 19,162a (abstract).
Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal,
G., Faivre, S., Sicard, E., Germa, C., Rodier, J.M., Vernillet, L., and
Armand, J.P. (2003) Multicentre phase II study and
pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients
with glioblastoma. Ann. Oncol.
14,603
-614.
Rivory, L.P. (1996) Irinotecan (CPT-11): A brief overview. Clin. Exp. Pharmacol. Physiol. 23,1000 -1004.[Web of Science][Medline]
Savaraj, N., Xu, R., Wu, C.J., Landy, H., Chua, L., Solomon, J., and Feun, L. (1995) Correlation of in vitro antitumor activity of irinotecan and topoi somerase I activity and levels in brain tumors. Proc. Am. Soc. Clin. Oncol. 14, 492 (abstract).
Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Con trol. Clin. Trials 10, 1-10.
Thompson, J., Houghton, J.A., and Houghton, P.J. (1996) Responses of neuroblastoma (Nb) xenografts to systemic administration of irinotecan. Proc. Am. Assoc. Cancer Res. 37,436 (abstract).
Vassal, G., Morizet, J., Bissery, M.-C., Boland, I., Ardouin, P., Mathieu-Boué, A., and Gouyette, A. (1994) Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenografts. Proc. Am. Assoc. Cancer Res. 35, 366 (abstract).
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro-oncol, January 1, 2009; 11(1): 80 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, D. F. Kraemer, and E. A. Neuwelt Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model Neuro-oncol, January 1, 2009; 11(2): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Quant, A. D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. LaFrankie, A. Ciampa, S. Kesari, and P. Y. Wen Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-oncol, January 1, 2009; 11(5): 550 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grossman, K. A. Carson, S. Phuphanich, T. Batchelor, D. Peereboom, L. B. Nabors, G. Lesser, F. Hausheer, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas Neuro-oncol, August 1, 2008; 10(4): 608 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Chamberlain Bevacizumab Plus Irinotecan in Recurrent Glioblastoma J. Clin. Oncol., February 20, 2008; 26(6): 1012 - 1013. [Full Text] [PDF]
|
|
|
|
|
|
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res., February 15, 2007; 13(4): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Prados, K. Lamborn, W.K.A. Yung, K. Jaeckle, H. I. Robins, M. Mehta, H. A. Fine, P. Y. Wen, T. Cloughesy, S. Chang, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study Neuro-oncol, April 1, 2006; 8(2): 189 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Shah, S. Kesari, R. Xu, T. T. Batchelor, A. M. O'Neill, F. H. Hochberg, B. Levy, J. Bradshaw, and P. Y. Wen Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas Neuro-oncol, January 1, 2006; 8(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Phuphanich, S. D. Baker, S. A. Grossman, K. A. Carson, M. R. Gilbert, J. D. Fisher, and M. A. Carducci Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study Neuro-oncol, April 1, 2005; 7(2): 177 - 182. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
